Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Salmonella enterica serovar Paratyphi A O-antigen lipopolysaccharide (S. Paratyphi A O:2 LPS; O-specific polysaccharide (OSP))
- Target
- S. Paratyphi A O:2 LPS; O-specific polysaccharide (OSP)
- Molecular classification
- Polysaccharide antigen, Bacterial surface antigen, Immunogen, Vaccine antigen
01
Overview
The O-antigen lipopolysaccharide of Salmonella enterica serovar Paratyphi A (O:2) is a major outer membrane component composed of a repeating trisaccharide backbone consisting of rhamnose, mannose, and galactose, with additional decorations including terminal paratose and glucose residues. This O-antigen serves as both an essential virulence factor and a protective antigen in infection with S. Paratyphi A, the causative agent of paratyphoid fever, a form of enteric fever in humans. The molecule is highly immunogenic when conjugated to carrier proteins such as CRM197, tetanus toxoid, or bacteriophage Qβ, generating functional antibody responses with bactericidal activity against diverse clinical isolates. Structural features including O-acetylation and glucosylation modifications are critical determinants of immunogenicity and vaccine efficacy. Multiple vaccine candidates utilizing O:2-based glycoconjugates are in clinical development, showing promise for broad protection against S. Paratyphi A despite natural structural variations among clinical strains.
- Other names
- O:2 antigenO-specific polysaccharide (OSP)O-antigenOuter membrane lipopolysaccharide of S. Paratyphi A
02
Mechanism of action
Antibody-mediated bacterial killing through bactericidal activity; Complement-dependent opsonization and destruction; Prevention of bacterial internalization into epithelial cells through immune recognition
03
Biological functions
Immune response (antigen recognition)Bacterial virulence (protective antigen)Cell surface antigen presentationVaccine target for protective immunity
04
Disease associations
Infection (enteric fever/paratyphoid fever caused by Salmonella Paratyphi A)
05
Safety considerations
None identified in vaccine development; well-tolerated in preclinical studiesNatural variation in O-antigen structure (O-acetylation and glucosylation) across clinical isolates requires consideration for broad vaccine coverage
06
Interacting drugs
Monoclonal antibodies (anti-O:2 antibodies generated through vaccination)
3 more in the full profile.
07
Biomarkers
Anti-O:2 IgG antibody levels (immunogenicity indicator)Serum bactericidal activity (SBA) against clinical S. Paratyphi A isolatesO-acetylation levels (60-80% range associated with vaccine efficacy)Glucosylation levels (vaccine response indicator)
Beyond the preview
Go deeper on Salmonella enterica serovar Paratyphi A O-antigen lipopolysaccharide (S. Paratyphi A O:2 LPS; O-specific polysaccharide (OSP)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Salmonella enterica serovar Paratyphi A O-antigen lipopolysaccharide (S. Paratyphi A O:2 LPS; O-specific polysaccharide (OSP)).